Pogz: A Potential Drug Target for Neurological Disorders (G23126)

Target Name: POGZ

NCBI ID: G23126

POGZ

Pogz: A Potential Drug Target for Neurological Disorders

Pogz (Paroxetine-Gabapentin) is a medication that is currently being investigated as a potential drug target (or biomarker) for various neurological disorders, including depression, anxiety, and pain. Paroxetine is an oral antidepressant that works by increasing the levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine, which can help to regulate mood and pain.

One of the reasons why Pogz is being investigated as a potential drug target is because it has been shown to have a wide range of potential therapeutic benefits in both humans and animals. For example, studies have shown that Pogz can be effective in treating symptoms of depression, anxiety, and pain, as well as in reducing the risk of relapse in individuals with depression.

In addition to its potential therapeutic benefits, Pogz is also being investigated as a potential biomarker for various neurological disorders. For example, some researchers have shown that the levels of Pogz in the brain can be affected by a variety of factors, such as stress, alcohol, and other drugs. This suggests that Pogz may be a useful biomarker for studying the effects of these factors on brain function.

Another reason why Pogz is being investigated as a potential drug target is because it has been shown to have a unique mechanism of action that may make it an effective treatment for certain neurological disorders. For example, some researchers have shown that Pogz works by increasing the levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine, which can help to regulate mood and pain. This is different from many other antidepressants, which work by altering the levels of certain neurotransmitters, such as serotonin and dopamine.

In addition to its unique mechanism of action, Pogz is also being investigated as a potential drug target because it has been shown to have a long half-life, which may make it an effective treatment for chronic neurological disorders. This means that Pogz can be present in the brain for a long period of time and can help to regulate mood and pain for longer periods of time than many other antidepressants.

Overall, Pogz is a medication that is being investigated as a potential drug target (or biomarker) for a wide range of neurological disorders. Its unique mechanism of action and long half-life, as well as its potential therapeutic benefits, make it an intriguing candidate for further research.

Protein Name: Pogo Transposable Element Derived With ZNF Domain

Functions: Plays a role in mitotic cell cycle progression and is involved in kinetochore assembly and mitotic sister chromatid cohesion. Probably through its association with CBX5 plays a role in mitotic chromosome segregation by regulating aurora kinase B/AURKB activation and AURKB and CBX5 dissociation from chromosome arms (PubMed:20562864). Promotes the repair of DNA double-strand breaks through the homologous recombination pathway (PubMed:26721387)

The "POGZ Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POGZ comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets